What are the key results of the TRIUMPH trials of retatrutide (a once‑weekly triple‑hormone receptor agonist targeting GIP (glucose‑dependent insulinotropic polypeptide), GLP‑1 (glucagon‑like peptide‑1), and glucagon) in adults with overweight/obesity, type 2 diabetes, and knee osteoarthritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

TRIUMPH Trial Results: Retatrutide for Obesity and Type 2 Diabetes

Retatrutide, a triple-hormone receptor agonist (GIP/GLP-1/glucagon), demonstrated superior weight loss and glycemic control compared to placebo in adults with obesity and type 2 diabetes, achieving mean weight reductions of 18.8% at the 12 mg dose and HbA1c reductions of 1.94% over 40-80 weeks. 1, 2

Key Efficacy Outcomes

TRIUMPH-2 (Obesity + Type 2 Diabetes, 80 weeks)

  • Study population: 1,152 adults with BMI ≥27 kg/m² and type 2 diabetes (HbA1c 6.5-10.5%), mean baseline BMI 38.2 kg/m², median diabetes duration 5.6 years 1
  • Weight loss results (treatment regimen estimand):
    • Retatrutide 4 mg: -11.9% (vs. -5.1% placebo; difference -6.9%, p<0.0001)
    • Retatrutide 9 mg: -16.8% (vs. placebo; difference -11.8%, p<0.0001)
    • Retatrutide 12 mg: -18.8% (vs. placebo; difference -13.8%, p<0.0001) 1
  • Completion rate: 84% completed study drug 1

TRANSCEND-T2D-1 (Type 2 Diabetes Monotherapy, 40 weeks)

  • Study population: 537 adults with type 2 diabetes inadequately controlled by diet/exercise alone (HbA1c 7.0-9.5%), mean baseline HbA1c 7.9%, mean BMI 35.8 kg/m² 2
  • Glycemic control (HbA1c reduction from baseline):
    • Retatrutide 4 mg: -1.69% (vs. -0.81% placebo; difference -0.88%, p<0.0001)
    • Retatrutide 9 mg: -1.86% (vs. placebo; difference -1.04%, p<0.0001)
    • Retatrutide 12 mg: -1.94% (vs. placebo; difference -1.12%, p<0.0001) 2
  • Weight loss results:
    • Retatrutide 4 mg: -11.5% (vs. -2.6% placebo)
    • Retatrutide 9 mg: -13.9%
    • Retatrutide 12 mg: -15.3% 2
  • Completion rate: 91% completed treatment period 2

Safety Profile

Common Adverse Events

The safety profile was consistent with GLP-1 receptor agonist class effects:

  • Gastrointestinal events (most frequent, generally mild-to-moderate, subsiding over time):

    • Diarrhea: 27-34% (retatrutide) vs. 13% (placebo) 1
    • Nausea: 14-28% (retatrutide) vs. 8% (placebo) 1

  • Dose-dependent events:

    • Hypotension: 1-6% (retatrutide) vs. <1% (placebo) 1
    • Dysesthesia: 4-7% (retatrutide) vs. 1% (placebo) 1

Treatment Discontinuation

  • TRIUMPH-2: Permanent discontinuation due to adverse events was 4% (4 mg), 12% (9 mg), 8% (12 mg) vs. 5% (placebo) 1
  • TRANSCEND-T2D-1: Discontinuation due to adverse events was 2-5% (retatrutide) vs. 0% (placebo) 2

Hypoglycemia and Mortality

  • No severe hypoglycemia reported in TRANSCEND-T2D-1 2
  • Deaths: 7 total deaths across TRIUMPH-2 (deemed unrelated to study drug by investigators) and 2 deaths in TRANSCEND-T2D-1 (both in 4 mg group, unrelated to study drug) 1, 2

Clinical Context and Positioning

Retatrutide's weight loss effects exceed those of currently available GLP-1 receptor agonists and tirzepatide (dual GIP/GLP-1 agonist), positioning it as a potentially superior option for adults with obesity and type 2 diabetes who prioritize weight reduction. 3 The 2025 BMJ living guideline acknowledges that approximately 90% of adults with type 2 diabetes have overweight or obesity, and growing evidence supports weight loss as an important treatment goal for this population 3.

Decision-Making Algorithm

For adults with type 2 diabetes and obesity:

  • Lower cardiovascular/kidney risk: Prioritize retatrutide for maximal weight loss (anticipated 15-19% reduction at 9-12 mg doses)
  • Higher cardiovascular/kidney risk (established CVD/CKD): Consider GLP-1 receptor agonists with established cardiovascular and kidney outcome benefits (higher certainty of evidence for mortality/MACE reduction), though retatrutide data are emerging 3
  • Baseline weight considerations: Apply proportional weight loss effects to individual body weight (trial baseline ~90 kg) 3

Important Caveats

  • Gastrointestinal tolerability: Higher doses (9-12 mg) associated with increased discontinuation rates (8-12%) compared to 4 mg (4%), requiring careful dose titration and patient counseling 1
  • Long-term cardiovascular outcomes: Unlike established GLP-1 receptor agonists and SGLT2 inhibitors, retatrutide lacks dedicated cardiovascular outcome trial data demonstrating mortality or MACE reduction 3, 4
  • Basket trial design: The TRIUMPH program includes nested protocols for obstructive sleep apnea and knee osteoarthritis, with results pending 5

References

Related Questions

How should retatrutide be administered, including dosing schedule, injection technique, and monitoring requirements?
What are the benefits, safety profile, and expected timeline for widespread availability of retatrutide?
What are the three receptors activated by retatrutide?
Does retatrutide reduce body weight and improve insulin resistance in patients with obesity and type 2 diabetes?
What is the appropriate dosing regimen of retatrutide for weight loss in an adult patient with obesity (BMI ≥ 30 kg/m²) without contraindications?
Is it safe to use Lovenox (enoxaparin) in a patient with an IgE‑mediated alpha‑gal allergy?
Does levetiracetam (Keppra) worsen schizophrenia?
Can injectable lorazepam be diluted in normal saline for intravenous administration in a convulsive emergency?
What are the signs and symptoms of Huntington's disease?
What is the appropriate clindamycin dose for an adult patient with impaired renal function (creatinine 2.5 mg/dL) and a diabetic foot infection?
What outpatient antihypertensive medication should be given to a post‑cesarean patient with a blood pressure of 160/100 mmHg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.